Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Accuray ( (ARAY) ) is now available.
On December 27, 2025, Accuray Incorporated announced that Byron C. Scott, a Class II director, will retire from its Board of Directors and all associated committees, effective December 31, 2025. The company stated that Scott’s decision to retire was not the result of any disagreement with Accuray’s management, board, or its operational policies and practices, indicating an orderly governance transition rather than a response to internal conflict.
The most recent analyst rating on (ARAY) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.
Spark’s Take on ARAY Stock
According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.
Accuray’s overall stock score is primarily impacted by its financial performance, characterized by declining revenues, negative profitability, and high leverage. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio. While the earnings call and corporate events highlight potential for future growth, current financial metrics and market conditions present significant challenges.
To see Spark’s full report on ARAY stock, click here.
More about Accuray
Accuray Incorporated operates in the medical technology industry, specializing in the development and manufacturing of radiation therapy systems used for cancer treatment and other medical conditions, serving hospitals and cancer treatment centers worldwide.
Average Trading Volume: 1,148,299
Technical Sentiment Signal: Sell
Current Market Cap: $91.24M
Find detailed analytics on ARAY stock on TipRanks’ Stock Analysis page.